These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15001337)

  • 1. Ximelagatran or warfarin in atrial fibrillation?
    MacAllister R; Hingorani AD; Casas JP
    Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
    [No Abstract]   [Full Text] [Related]  

  • 2. Ximelagatran or warfarin in atrial fibrillation?
    Eikelboom J; Hankey G
    Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
    [No Abstract]   [Full Text] [Related]  

  • 3. Ximelagatran or warfarin in atrial fibrillation?
    Stöllberger C; Finsterer J
    Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ximelagatran or warfarin in atrial fibrillation?
    Epstein EF
    Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
    Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
    Berry C; Norrie J; McMurray JJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H
    Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Cavuşoğlu Y
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
    [No Abstract]   [Full Text] [Related]  

  • 12. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation for atrial fibrillation in the elderly.
    Halperin JL
    Am J Geriatr Cardiol; 2005; 14(2):81-6. PubMed ID: 15785149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Kiraç FS
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):214-5; author reply 218-9. PubMed ID: 17513229
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Tandoğan I
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):216; author reply 218-9. PubMed ID: 17513230
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
    Cleland JG; Shelton R; Nikitin N; Ford S; Frison L; Grind M
    Eur J Heart Fail; 2007; 9(6-7):730-9. PubMed ID: 17360232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.